Solid Biosciences (SLDB) Competitors $4.74 -0.09 (-1.76%) As of 10:39 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SLDB vs. CALT, AMPH, AUPH, ELVN, WVE, MLYS, RCUS, CVAC, SYRE, and PAHCShould you be buying Solid Biosciences stock or one of its competitors? The main competitors of Solid Biosciences include Calliditas Therapeutics AB (publ) (CALT), Amphastar Pharmaceuticals (AMPH), Aurinia Pharmaceuticals (AUPH), Enliven Therapeutics (ELVN), Wave Life Sciences (WVE), Mineralys Therapeutics (MLYS), Arcus Biosciences (RCUS), CureVac (CVAC), Spyre Therapeutics (SYRE), and Phibro Animal Health (PAHC). These companies are all part of the "pharmaceutical products" industry. Solid Biosciences vs. Calliditas Therapeutics AB (publ) Amphastar Pharmaceuticals Aurinia Pharmaceuticals Enliven Therapeutics Wave Life Sciences Mineralys Therapeutics Arcus Biosciences CureVac Spyre Therapeutics Phibro Animal Health Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Solid Biosciences (NASDAQ:SLDB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, community ranking, valuation, profitability, risk, earnings, dividends and media sentiment. Which has more risk and volatility, CALT or SLDB? Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500. Comparatively, Solid Biosciences has a beta of 2.22, meaning that its share price is 122% more volatile than the S&P 500. Do analysts rate CALT or SLDB? Solid Biosciences has a consensus price target of $14.90, indicating a potential upside of 208.49%. Given Solid Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Solid Biosciences is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Solid Biosciences 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 3 Strong Buy rating(s) 3.23 Which has higher earnings and valuation, CALT or SLDB? Calliditas Therapeutics AB (publ) has higher revenue and earnings than Solid Biosciences. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62Solid Biosciences$8.09M46.28-$96.01M-$2.99-1.62 Does the media favor CALT or SLDB? In the previous week, Solid Biosciences had 9 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 9 mentions for Solid Biosciences and 0 mentions for Calliditas Therapeutics AB (publ). Solid Biosciences' average media sentiment score of 0.74 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Solid Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Calliditas Therapeutics AB (publ) Neutral Solid Biosciences Positive Does the MarketBeat Community believe in CALT or SLDB? Solid Biosciences received 255 more outperform votes than Calliditas Therapeutics AB (publ) when rated by MarketBeat users. Likewise, 69.46% of users gave Solid Biosciences an outperform vote while only 55.10% of users gave Calliditas Therapeutics AB (publ) an outperform vote. CompanyUnderperformOutperformCalliditas Therapeutics AB (publ)Outperform Votes2755.10% Underperform Votes2244.90% Solid BiosciencesOutperform Votes28269.46% Underperform Votes12430.54% Is CALT or SLDB more profitable? Solid Biosciences has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Solid Biosciences' return on equity of -58.75% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Calliditas Therapeutics AB (publ)-30.18% -212.04% -27.96% Solid Biosciences N/A -58.75%-47.84% Do insiders and institutionals believe in CALT or SLDB? 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Comparatively, 1.9% of Solid Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummarySolid Biosciences beats Calliditas Therapeutics AB (publ) on 14 of the 19 factors compared between the two stocks. Get Solid Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SLDB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLDB vs. The Competition Export to ExcelMetricSolid BiosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$374.40M$3.10B$5.57B$8.66BDividend YieldN/A1.59%5.27%4.19%P/E Ratio-1.5933.8227.2020.17Price / Sales46.28476.37412.92161.90Price / CashN/A168.6838.2534.64Price / Book0.773.497.114.72Net Income-$96.01M-$72.35M$3.23B$247.80M7 Day Performance38.00%10.49%4.61%3.36%1 Month Performance74.37%24.23%13.35%9.71%1 Year Performance-38.24%-15.55%31.75%14.41% Solid Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLDBSolid Biosciences3.6912 of 5 stars$4.77-1.2%$14.90+212.2%-38.2%$369.98M$8.09M-1.57100Analyst RevisionCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180AMPHAmphastar Pharmaceuticals3.6195 of 5 stars$25.24-2.4%$32.33+28.1%-35.4%$1.19B$730.66M8.411,620Positive NewsAUPHAurinia Pharmaceuticals3.3037 of 5 stars$8.12+1.6%$11.50+41.7%+50.9%$1.10B$247.30M-54.10300Positive NewsAnalyst RevisionELVNEnliven Therapeutics2.707 of 5 stars$22.39+0.4%$37.25+66.4%-3.9%$1.09BN/A-11.7150WVEWave Life Sciences4.2896 of 5 stars$6.71+0.4%$21.17+215.4%+22.5%$1.03B$104.94M-6.03240Positive NewsAnalyst RevisionMLYSMineralys Therapeutics2.7252 of 5 stars$15.58+0.4%$38.00+144.0%+18.7%$1.01BN/A-4.2828Positive NewsAnalyst ForecastRCUSArcus Biosciences2.7521 of 5 stars$9.51-0.9%$24.13+153.7%-37.7%$1.00B$141M-3.01500Analyst RevisionGap UpCVACCureVac4.0935 of 5 stars$4.42-0.5%$11.00+148.9%-7.0%$993.82M$523.70M8.05880SYRESpyre Therapeutics2.2786 of 5 stars$16.49-0.2%$53.40+223.9%-49.1%$989.73M$890,000.00-2.2073PAHCPhibro Animal Health3.6688 of 5 stars$24.01+0.2%$20.00-16.7%+43.8%$968.97M$1.19B49.801,860Positive News Related Companies and Tools Related Companies Calliditas Therapeutics AB (publ) Competitors Amphastar Pharmaceuticals Competitors Aurinia Pharmaceuticals Competitors Enliven Therapeutics Competitors Wave Life Sciences Competitors Mineralys Therapeutics Competitors Arcus Biosciences Competitors CureVac Competitors Spyre Therapeutics Competitors Phibro Animal Health Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLDB) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Solid Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Solid Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
